Physician profile
Lorrie J Klein
NPI 1508852799
$13,106.44
in general payments reported to CMS, 2019-2025
21 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,590 · 2020: $613 · 2021: $626 · 2022: $674 · 2023: $4,182 · 2024: $1,400 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,734 · Consulting Fee: $2,500 · Travel and Lodging: $342 · Education: $26.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,733.79 |
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $342.27 |
| Education | $26.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,230.06 | 2019-2022 | |
| Abbvie INC. | $4,835.67 | 2019-2025 | |
| Revance Therapeutics, INC. | $1,325.39 | 2024-2025 | Daxxify |
| Merz North America, INC. | $460.16 | 2020-2025 | |
| Leo Pharma INC. | $306.37 | 2021-2025 | Adbry |
| Pfizer INC. | $244.67 | 2019-2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $165.30 | 2019 | |
| Genzyme Corporation | $129.87 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $81.02 | 2024-2025 | |
| Galderma Laboratories, L.P. | $51.34 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $45.40 | 2021 | |
| Cipher Pharmaceuticals US LLC | $40.67 | 2025 | Natroba, Spinosad |
| E.R. Squibb & Sons, L.L.C. | $30.21 | 2022 | |
| Ucb, INC. | $28.22 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $26.79 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $25.50 | 2023 | Seysara |
| Regeneron Healthcare Solutions, INC. | $19.51 | 2025 | Dupixent |
| Lilly USA, LLC | $17.49 | 2022 | |
| Medtronic, INC. | $15.85 | 2024 | Venaseal |
| Incyte Corporation | $14.09 | 2024 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorrie Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.